title: Repurposing Antiestrogens for Tumor Immunotherapy.
abstract: Svoronos and colleagues observed estrogen receptor alpha-positive cells in the tumor stroma of patients with ovarian cancer that appeared to be independent of both the tumor's estrogen receptor status and tumor type. These cells were identified as immunosuppressive myeloid-derived suppressor cells (MDSC) and could be targeted by antiestrogen therapy, thereby leading to the hypothesis that endocrine therapy when combined with immunotherapy may provide a potential therapeutic benefit by helping to reduce immunosuppressive MDSCs. Cancer Discov; 7(1); 17-9. ©2017 AACRSee related article by Svoronos et al., 72.
authors.affiliation: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
authors.forename: Thomas
authors.initials: T
authors.lastname: Welte
authors.affiliation: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
authors.forename: Xiang H-F
authors.initials: XH
authors.lastname: Zhang
authors.affiliation: Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas. jrosen@bcm.edu.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Rosen
mesh_terms: D020847:Estrogen Receptor Modulators; D006801:Humans; D007167:Immunotherapy; D022423:Myeloid Cells; D000072737:Myeloid-Derived Suppressor Cells; D009369:Neoplasms
chemical_list: D020847:Estrogen Receptor Modulators